Virus-Immunotherapy duo targets Hard-to-Treat colorectal cancer
NCT ID NCT07411781
First seen Feb 18, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This early-phase study tests a combination of a specially designed virus (PIN) and an immunotherapy drug (sintilimab) in up to 25 adults with advanced colorectal cancer that has spread to the liver and hasn't responded to at least two prior treatments. The goal is to see if this approach is safe and can shrink tumors or slow the disease. Participants will receive both treatments and be closely monitored for side effects and immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.